Rheumatische Erkrankungen im Alter

Zurück zum Zitat Tengstrand B, Ahlmén M, Hafström I (2004) The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 31(2):214–222PubMed Tengstrand B, Ahlmén M, Hafström I (2004) The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. J Rheumatol 31(2):214–222PubMed

Zurück zum Zitat Symmons DP (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16(5):707–722CrossRef Symmons DP (2002) Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol 16(5):707–722CrossRef

Zurück zum Zitat Kobak S, Bes C (2018) An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis 10(1):3–11CrossRef Kobak S, Bes C (2018) An autumn tale: geriatric rheumatoid arthritis. Ther Adv Musculoskelet Dis 10(1):3–11CrossRef

Zurück zum Zitat Böhler C, Radner H, Ernst M, Binder A, Stamm T, Aletaha D, Smolen JS, Köller M (2012) Rheumatoid arthritis and falls: the influence of disease activity. Rheumatology 51(11):2051–2057CrossRef Böhler C, Radner H, Ernst M, Binder A, Stamm T, Aletaha D, Smolen JS, Köller M (2012) Rheumatoid arthritis and falls: the influence of disease activity. Rheumatology 51(11):2051–2057CrossRef

Zurück zum Zitat Tada M, Yamada Y, Mandai K, Hidaka N (2019) Correlation between frailty and disease activity in patients with rheumatoid arthritis: data from the CHIKARA study. Geriatr Gerontol Int 19(12):1220–1225CrossRef Tada M, Yamada Y, Mandai K, Hidaka N (2019) Correlation between frailty and disease activity in patients with rheumatoid arthritis: data from the CHIKARA study. Geriatr Gerontol Int 19(12):1220–1225CrossRef

Zurück zum Zitat Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology 48(8):906–910CrossRef Radovits BJ, Fransen J, Eijsbouts A, van Riel PL, Laan RF (2009) Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology 48(8):906–910CrossRef

Zurück zum Zitat Tan TC, Gao X, Thong BY, Leong KP, Lian TY, Law WG, Kong KO, Howe HS, Chng HH, Koh ET, TTSH Rheumatoid Arthritis Study Group (2017) Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis 20(6):737–745CrossRef Tan TC, Gao X, Thong BY, Leong KP, Lian TY, Law WG, Kong KO, Howe HS, Chng HH, Koh ET, TTSH Rheumatoid Arthritis Study Group (2017) Comparison of elderly- and young-onset rheumatoid arthritis in an Asian cohort. Int J Rheum Dis 20(6):737–745CrossRef

Zurück zum Zitat Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS (2009) Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 48(12):1575–1580CrossRef Köller MD, Aletaha D, Funovits J, Pangan A, Baker D, Smolen JS (2009) Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. Rheumatology 48(12):1575–1580CrossRef

Zurück zum Zitat Soubrier M, Lahaye C, Tatar Z (2018) Abatacept for treatment of rheumatoid arthritis: special focus on the elderly. Drugs Aging 35(5):379–387CrossRef Soubrier M, Lahaye C, Tatar Z (2018) Abatacept for treatment of rheumatoid arthritis: special focus on the elderly. Drugs Aging 35(5):379–387CrossRef

Zurück zum Zitat Edwards CJ, Roshak K, Bukowski JF, Pedersen R, Thakur M, Borlenghi C, Curiale C, Jones H, Marshall L (2019) Efficacy and safety of etanercept in elderly patients with rheumatoid arthritis: a post-hoc analysis of randomized controlled trials. Drugs Aging 36(9):853–862CrossRef Edwards CJ, Roshak K, Bukowski JF, Pedersen R, Thakur M, Borlenghi C, Curiale C, Jones H, Marshall L (2019) Efficacy and safety of etanercept in elderly patients with rheumatoid arthritis: a post-hoc analysis of randomized controlled trials. Drugs Aging 36(9):853–862CrossRef

Zurück zum Zitat Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A (2019) Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged 〈 65 years and those ≥ 65 years of age. Arthritis Res Ther 21(1):190CrossRef Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A (2019) Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged 〈 65 years and those ≥ 65 years of age. Arthritis Res Ther 21(1):190CrossRef

Zurück zum Zitat Schütz N, Sixdorf U, Märker-Hermann E (2012) Inflammatory rheumatic diseases in the elderly. Dtsch Med Wochenschr 137(15):793–798CrossRef Schütz N, Sixdorf U, Märker-Hermann E (2012) Inflammatory rheumatic diseases in the elderly. Dtsch Med Wochenschr 137(15):793–798CrossRef

Zurück zum Zitat Li H, Altman RD, Yao Q (2015) RS3PE: Clinical and Research Development. Curr Rheumatol Rep 17(8):49CrossRef Li H, Altman RD, Yao Q (2015) RS3PE: Clinical and Research Development. Curr Rheumatol Rep 17(8):49CrossRef

Zurück zum Zitat Iqbal SM, Qadir S, Aslam HM, Qadir MA (2019) Updated treatment for calcium pyrophosphate deposition disease: an insight. Cureus 11(1):e3840–7PubMedPubMedCentral Iqbal SM, Qadir S, Aslam HM, Qadir MA (2019) Updated treatment for calcium pyrophosphate deposition disease: an insight. Cureus 11(1):e3840–7PubMedPubMedCentral

Zurück zum Zitat Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Amo MD, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71(4):484–492CrossRef Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, Bachta A, Dejaco C, Duftner C, Jensen HS, Duhaut P, Poór G, Kaposi NP, Mandl P, Balint PV, Schmidt Z, Iagnocco A, Nannini C, Cantini F, Macchioni P, Pipitone N, Amo MD, Espígol-Frigolé G, Cid MC, Martínez-Taboada VM, Nordborg E, Direskeneli H, Aydin SZ, Ahmed K, Hazleman B, Silverman B, Pease C, Wakefield RJ, Luqmani R, Abril A, Michet CJ, Marcus R, Gonter NJ, Maz M, Carter RE, Crowson CS, Matteson EL (2012) 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 71(4):484–492CrossRef

Zurück zum Zitat Dejaco C, Matteson EL, Buttgereit F (2016) Diagnostics and treatment of polymyalgia rheumatica. Z Rheumatol 75(7):687–700CrossRef Dejaco C, Matteson EL, Buttgereit F (2016) Diagnostics and treatment of polymyalgia rheumatica. Z Rheumatol 75(7):687–700CrossRef

Zurück zum Zitat Buttgereit F, Brabant T, Dinges H, Hiemer I, Rheuma-Liga, Kaplani M, Kiltz U, Kyburz D, Reißhauer A, Schneider M, Weseloh C, Dejaco C (2018) S3 guidelines on treatment of polymyalgia rheumatica : evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77(5):429–441CrossRef Buttgereit F, Brabant T, Dinges H, Hiemer I, Rheuma-Liga, Kaplani M, Kiltz U, Kyburz D, Reißhauer A, Schneider M, Weseloh C, Dejaco C (2018) S3 guidelines on treatment of polymyalgia rheumatica : evidence-based guidelines of the German Society of Rheumatology (DGRh), the Austrian Society of Rheumatology and Rehabilitation (ÖGR) and the Swiss Society of Rheumatology (SGT) and participating medical scientific specialist societies and other organizations. Z Rheumatol 77(5):429–441CrossRef

Zurück zum Zitat Lally L, Forbess L, Hatzis C, Spiera R (2016) Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68(10):2550–2554CrossRef Lally L, Forbess L, Hatzis C, Spiera R (2016) Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol 68(10):2550–2554CrossRef

Zurück zum Zitat Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 56(4):506–515PubMed Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology 56(4):506–515PubMed

Zurück zum Zitat Dechant C, Schulze-Koops H (2019) Update giant cell arteriitis. Dtsch Med Wochenschr 144(20):1432–1436CrossRef Dechant C, Schulze-Koops H (2019) Update giant cell arteriitis. Dtsch Med Wochenschr 144(20):1432–1436CrossRef

Zurück zum Zitat Salvarani C, Hunder GG (2001) Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum 45(2):140–145CrossRef Salvarani C, Hunder GG (2001) Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum 45(2):140–145CrossRef

Zurück zum Zitat Esposito AL, Gleckman RA (1978) Fever of unknown origin in the elderly. J Am Geriatr Soc 26(11):498–505CrossRef Esposito AL, Gleckman RA (1978) Fever of unknown origin in the elderly. J Am Geriatr Soc 26(11):498–505CrossRef

Zurück zum Zitat Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122(7):502–507CrossRef Evans JM, O’Fallon WM, Hunder GG (1995) Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 122(7):502–507CrossRef

Zurück zum Zitat Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19–30CrossRef Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA (2020) 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79(1):19–30CrossRef